Katharine J. Bar, MD
Travel Medicine, Infectious Diseases
Accepting new patients
Sees patients age 18 and up
MacGregor Infection Medicine and Travel Program
View 1 additional location
Penn Medicine Provider

About me

  • Director, Virology Core, Penn Center for AIDS Research
  • Associate Professor of Medicine (Infectious Diseases)

Education and training

  • Medical School: University of Iowa College of Medicine
  • Residency: Virginia Commonwealth University School of Medicine
  • Fellowship: University of Alabama Medical Center

What my patients think about me

Average Rating

72 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
February 2026
dr. bar is very thorough and knowledgeable. has bought me through a critical crisis with excellent results!
Anonymous
February 2026
she is very knowledgeable on infectious disease's i would recommend her to everybody
Anonymous
January 2026
i have been with doctor bar for over 10year
Anonymous
January 2026
i really appreciate all my DR. Bar do for me, she's very caring

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Bar is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Murphy T, Kelly M, Shimagaki KS, DeStefanis T, Galeotos G, Lee M, Wei Q, Novak J, Bar KJ, Barton JP, Lynch RM. Dual Role of Glycosylation in Resistance to CD4-binding Site Broadly Neutralizing Antibodies. , J Virol: 2026


Pache L, Bui JK, Klouser LM, Fennessey CM, Noyola AC, Einhaus T, Zhu H, Stensland L, Leguizamo I, Koroma AA, Teriete P, Chang WLW, Hyrien O, Duggan NN, Heimann D, Pérez-Osorio AC, Bar KJ, Cosford ND, Keele BF, Hartigan-O'Connor DJ, Farzan M, Gardner MR, Jerome KR, Chanda SK, Kiem HP, Peterson CW. Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques , J Clin Invest, 136((6):e187961): 2026


Ndung'u T, Dong KL, Colby DJ, Deeks SG, Cotton MF, Dubé K, Goulder PJ, Julg B, Nsubuga M, Ajibola G, Bar KJ, Bengu N, Bwakura-Dangarembizi M, Caskey M, Cromhout G, Kekitiinwa AR, Kilembe W, Kuhn L, Likhitwonnawut U, Mgodi NM, Persaud D, Peluso MJ, Rasmussen TA, Romo M, Sacdalan C, Samaneka W, Shapiro R, Søgaard OS, Tudor-Williams G, Wambui C, Tressler R, Lewin SR, Crowell TA, Kasprowicz VO, Trautmann L. 2nd ATI Consensus Workshop. Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials , Lancet HIV, S2352-3018(25): 2026,00373-X


Murray J, Einhaus T, Radtke S, Bar KJ, Peterson CW, Kiem HP. Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates , Blood Adv, 10(4): 2026,1094-1105


Taiwo BO, Zheng Y, Rodriguez K, Burke L, Reeves JD, Scarsi KK, Gama L, Petropoulos CJ, Belaunzaran-Zamudio PF, Wannamaker P, D'Amico R, Rathod P, Bar KJ, Tebas P; A5357 Study Team. Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357 , Clin Infect Dis, 82(1): 2026,100-108


Habib R, Roark RS, Li H, Connell AJ, Hogarty MP, Wagh K, Wang S, Marchitto L, Skelly AN, Carey JW, Sowers KJ, Ayyanathan K, Plante SJ, Bibollet-Ruche F, Park Y, Agostino CJ, Singh A, Martella CL, Lewis E, Rando JM, Chohan N, Lora J, Ding W, Campion MS, Zhao C, Liu W, Li Y, Li X, Liang B, Chowdhury RR, Amereh K, Van Itallie E, Sheng Z, Ghosh AR, Bar KJ, Williams WB, Wiehe K, Saunders KO, Edwards RJ, Cain DW, Lewis MG, Batista FD, Burton DR, Andrabi R, Kulp DW, Haynes BF, Korber B, Shapiro L, Kwong PD, Hahn BH, Shaw GM. Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development , Sci Immunol, 11(116): 2026,eadz3933


Smith NM, Ho BM, Bar KJ, Gama L, Dziubla G, Koup RA, Pensiero M, Serebryannyy L, Caskey M, Wilkin TJ, Wood TD, Morse GD, Venuto CS, Cha R, Ma Q. Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis , Clin Transl Sci, 19(2): 2026,e70488


Podgorski RM, Yarmahmoodi A, Baak S, Warfield R, Robinson JA, Roof J, Caocci M, Fazelinia H, Spruce LA, Bar KJ, Burdo TH. SHIV.D Infection Alters Production and Protein Composition of Myeloid-Derived Extracellular Vesicles , Int J Mol Sci, 27(2): 2026,966


Pampena MB, Samer S, Viox EG, Nguyen K, Deleage C, Kuri-Cervantes L, Regan J, Wu VH, Docken S, Safrit JT, Bar KJ, Keele BF, Davenport MP, Paiardini M, Betts MR. Therapeutic CD8+ T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound. , Proc Natl Acad Sci U S A., 122(33): 2025


Karuna S, Laher F, Dadabhai S, Yu PC, Grove D, Orrell C, Makhema J, Hosseinipour MC, Mathew CA, Brumskine W, Mgodi N, Andrew P, Gama L, Karg C, Broder G, Baepanye K, Lucas J, Andrasik M, Takuva S, Villaran M, Takalani A, Tressler R, Soto-Torres L, Woodward Davis AS, Dhai A, Sanne IM, Cohen MS, Corey L, Gray G, deCamp AC, Bar KJ Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data. , J Int AIDS Soc, 28(6): 2025,e26495